OBJECTIVE: Left ventricular assist device support mechanically unloads the failing ventricle with resultant improvement in cardiac geometry and function in patients with end-stage heart failure. Activation of the G alpha q signaling pathway, including protein kinase C, appears to be involved in the progression of heart failure. Similarly down-regulation of Ca2+ cycling proteins may contribute to contractile depression in this clinical syndrome. Thus we examined whether protein kinase C activation and decreased Ca2+ cycling protein levels could be reversed by left ventricular assist device support. METHODS: Left ventricular myocardial specimens were obtained from seven patients during placement of left ventricular assist device and heart transplantation. We examined changes in protein levels of G alpha q, phospholipase C beta 1, regulators of G protein signaling (RGS), sarcoplasmic reticulum Ca2+ ATPase, phospholamban and translocation of protein kinase C isoforms (alpha, beta 1, and beta 2). RESULTS: The paired pre- and post-left ventricular assist device samples revealed that RGS2, a selective inhibitor of G alpha q, was decreased (P < 0.01), while the status of G alpha q, phospholipase C beta 1, RGS3 and RGS4 were unchanged after left ventricular assist device implantation. Translocation of protein kinase C isoforms remained unchanged. Left ventricular assist device support increased sarcoplasmic reticulum Ca2+ ATPase protein level (P < 0.01), while phospholamban abundance was unchanged. CONCLUSIONS: We conclude that altered protein expression and stoichiometry of the major cardiomyocyte Ca2+ cycling proteins rather than reduced phospholipase C beta 1 activation may contribute to improved mechanical function produced by left ventricular assist device support in human heart failure.
OBJECTIVE: Left ventricular assist device support mechanically unloads the failing ventricle with resultant improvement in cardiac geometry and function in patients with end-stage heart failure. Activation of the G alpha q signaling pathway, including protein kinase C, appears to be involved in the progression of heart failure. Similarly down-regulation of Ca2+ cycling proteins may contribute to contractile depression in this clinical syndrome. Thus we examined whether protein kinase C activation and decreased Ca2+ cycling protein levels could be reversed by left ventricular assist device support. METHODS: Left ventricular myocardial specimens were obtained from seven patients during placement of left ventricular assist device and heart transplantation. We examined changes in protein levels of G alpha q, phospholipase C beta 1, regulators of G protein signaling (RGS), sarcoplasmic reticulum Ca2+ ATPase, phospholamban and translocation of protein kinase C isoforms (alpha, beta 1, and beta 2). RESULTS: The paired pre- and post-left ventricular assist device samples revealed that RGS2, a selective inhibitor of G alpha q, was decreased (P < 0.01), while the status of G alpha q, phospholipase C beta 1, RGS3 and RGS4 were unchanged after left ventricular assist device implantation. Translocation of protein kinase C isoforms remained unchanged. Left ventricular assist device support increased sarcoplasmic reticulum Ca2+ ATPase protein level (P < 0.01), while phospholamban abundance was unchanged. CONCLUSIONS: We conclude that altered protein expression and stoichiometry of the major cardiomyocyte Ca2+ cycling proteins rather than reduced phospholipase C beta 1 activation may contribute to improved mechanical function produced by left ventricular assist device support in humanheart failure.
Authors: Konstantinos G Malliaras; John V Terrovitis; Stavros G Drakos; John N Nanas Journal: J Cardiovasc Transl Res Date: 2008-09-30 Impact factor: 4.132
Authors: Leanne Elizabeth Felkin; Enrique A Lara-Pezzi; Jennifer L Hall; Emma J Birks; Paul J R Barton Journal: J Cardiovasc Transl Res Date: 2011-03-22 Impact factor: 4.132
Authors: Stavros G Drakos; Abdallah G Kfoury; Craig H Selzman; Divya Ratan Verma; John N Nanas; Dean Y Li; Josef Stehlik Journal: Curr Opin Cardiol Date: 2011-05 Impact factor: 2.161
Authors: Nazha Hamdani; Monique de Waard; Andrew E Messer; Nicky M Boontje; Viola Kooij; Sabine van Dijk; Amanda Versteilen; Regis Lamberts; Daphne Merkus; Cris Dos Remedios; Dirk J Duncker; Attila Borbely; Zoltan Papp; Walter Paulus; Ger J M Stienen; Steven B Marston; Jolanda van der Velden Journal: J Muscle Res Cell Motil Date: 2009-01-13 Impact factor: 2.698
Authors: Zsuzsanna Callaerts-Vegh; Kenda L J Evans; Gregory L Shipley; Peter J A Davies; Donald L Cuba; Hunaid A Gurji; Heather Giles; Richard A Bond Journal: Br J Pharmacol Date: 2003-04 Impact factor: 8.739
Authors: Andreas A Werdich; Anna Brzezinski; Darwin Jeyaraj; M Khaled Sabeh; Eckhard Ficker; Xiaoping Wan; Brian M McDermott; Calum A Macrae; David S Rosenbaum Journal: Prog Biophys Mol Biol Date: 2012-07-23 Impact factor: 3.667
Authors: Hyosook Hwang; Dustin A Robinson; Tamara K Stevenson; Helen C Wu; Sarah E Kampert; Francis D Pagani; D Brad Dyke; Jody L Martin; Sakthival Sadayappan; Sharlene M Day; Margaret V Westfall Journal: J Mol Cell Cardiol Date: 2012-05-14 Impact factor: 5.000